Literature DB >> 7863231

The influence of N-acetylcysteine on the measurement of prothrombin time and activated partial thromboplastin time in healthy subjects.

S Jepsen1, A B Hansen.   

Abstract

The purpose of the study was to evaluate whether the infusion of N-acetylcysteine decreased the measurement of prothrombin time and activated partial thromboplastin time (APTT) in healthy persons. N-acetylcysteine was administered intraveneously 10 mg kg-1 as a loading dose and then at a rate of 10 mg kg-1 h-1 for 32 h in six male subjects. The intrinsic, extrinsic and common pathway of coagulation were monitored with activated partial thromboplastin time (APTT), and prothrombin time, respectively. In addition, the extrinsic coagulation pathway was monitored with the clotting activity of single factors II, VII, and X. No effect on the intrinsic coagulation pathway was observed. There was a significant and rapid decrease in prothrombin time. Coagulation factors II, VII and X, the three components of prothrombin time, decreased significantly to different degrees. We conclude that infusion of N-acetylcysteine intraveneously decreases the prothrombin time in healthy subjects. Thus, one should not make conclusions which are too far-reaching based on prothrombin time alone in patients who have been treated recently with N-acetylcysteine intraveneously.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7863231     DOI: 10.3109/00365519409088566

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  In vitro study of N-acetylcysteine on coagulation factors in plasma samples from healthy subjects.

Authors:  David H Jang; Matthew D Weaver; Anthony F Pizon
Journal:  J Med Toxicol       Date:  2013-03

2.  N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.

Authors:  Junmei Chen; Adili Reheman; Francisca C Gushiken; Leticia Nolasco; Xiaoyun Fu; Joel L Moake; Heyu Ni; José A López
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

3.  Thrombotic thrombocytopenic purpura: reducing the risk?

Authors:  Michael C Berndt; Robert K Andrews
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

4.  Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects.

Authors:  T T Knudsen; S Thorsen; S A Jensen; K Dalhoff; L E Schmidt; U Becker; F Bendtsen
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

5.  The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura.

Authors:  Amihai Rottenstreich; Sarit Hochberg-Klein; Deborah Rund; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

6.  Comparison of Prothrombin Time and Aspartate Aminotransferase in Predicting Hepatotoxicity After Acetaminophen Overdose.

Authors:  Michael Levine; Ayrn D O'Connor; Angela Padilla-Jones; Richard D Gerkin
Journal:  J Med Toxicol       Date:  2016-03

7.  NAC changes the course of cerebral small vessel disease in SHRSP and reveals new insights for the meaning of stases - a randomized controlled study.

Authors:  Celine Zoe Bueche; Cornelia Garz; Siegfried Kropf; Daniel Bittner; Wenjie Li; Michael Goertler; Hans-Jochen Heinze; Klaus Reymann; Holger Braun; Stefanie Schreiber
Journal:  Exp Transl Stroke Med       Date:  2013-04-15

Review 8.  Preventing the development of severe COVID-19 by modifying immunothrombosis.

Authors:  Gerwyn Morris; Chiara C Bortolasci; Basant K Puri; Lisa Olive; Wolfgang Marx; Adrienne O'Neil; Eugene Athan; Andre Carvalho; Michael Maes; Ken Walder; Michael Berk
Journal:  Life Sci       Date:  2020-10-20       Impact factor: 5.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.